ATE412013T1 - Anti-osteopontin-antikörper und dessen verwendung - Google Patents

Anti-osteopontin-antikörper und dessen verwendung

Info

Publication number
ATE412013T1
ATE412013T1 AT02713293T AT02713293T ATE412013T1 AT E412013 T1 ATE412013 T1 AT E412013T1 AT 02713293 T AT02713293 T AT 02713293T AT 02713293 T AT02713293 T AT 02713293T AT E412013 T1 ATE412013 T1 AT E412013T1
Authority
AT
Austria
Prior art keywords
osteopontin antibodies
osteopontin
antibodies
Prior art date
Application number
AT02713293T
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Yukihiko Saeki
Yasuyuki Yokosaki
Masaki Noda
Nobuchika Yamamoto
Original Assignee
Immuno Biological Lab Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd, Astellas Pharma Inc filed Critical Immuno Biological Lab Co Ltd
Application granted granted Critical
Publication of ATE412013T1 publication Critical patent/ATE412013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02713293T 2001-04-05 2002-04-04 Anti-osteopontin-antikörper und dessen verwendung ATE412013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001107578 2001-04-05
JP2001290700 2001-09-25

Publications (1)

Publication Number Publication Date
ATE412013T1 true ATE412013T1 (de) 2008-11-15

Family

ID=26613159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713293T ATE412013T1 (de) 2001-04-05 2002-04-04 Anti-osteopontin-antikörper und dessen verwendung

Country Status (20)

Country Link
US (2) US20040234524A1 (de)
EP (2) EP1754719A3 (de)
JP (1) JP4230776B2 (de)
KR (1) KR100881900B1 (de)
CN (1) CN100469793C (de)
AR (1) AR033121A1 (de)
AT (1) ATE412013T1 (de)
AU (1) AU2002244968B2 (de)
BR (1) BR0208809A (de)
CA (1) CA2443330A1 (de)
CZ (1) CZ20032697A3 (de)
DE (1) DE60229509D1 (de)
ES (1) ES2314040T3 (de)
HU (1) HUP0401561A2 (de)
MX (1) MXPA03009052A (de)
NO (1) NO20034405L (de)
NZ (1) NZ528483A (de)
PL (1) PL366469A1 (de)
RU (1) RU2299888C2 (de)
WO (1) WO2002081522A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002341488A1 (en) 2001-05-09 2002-11-18 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
EP2143438B1 (de) 2001-09-18 2011-07-13 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
AU2002332290B2 (en) * 2001-09-25 2007-11-08 Astellas Pharma Inc. Recombinant anti-osteopontin antibody and use thereof
WO2006043954A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JPWO2004103403A1 (ja) * 2003-05-23 2006-07-20 株式会社 免疫生物研究所 免疫担当細胞活性化阻害剤およびその用途
WO2005020785A2 (en) * 2003-07-15 2005-03-10 The Regents Of The University Of California Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
CN101103044B (zh) 2005-01-13 2013-01-02 株式会社遗传科技 抗α9整联蛋白抗体及其用途
ES2384350T3 (es) * 2006-05-31 2012-07-04 Astellas Pharma Inc. Anticuerpo anti-osteopontina humana humanizado
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
AU2007273467B2 (en) 2006-07-12 2012-10-04 Gene Techno Science Co., Ltd. Antihuman alpha9 integrin antibody and use of the same
US7981672B2 (en) 2006-09-11 2011-07-19 Immuno-Biological Laboratories Co., Ltd. Monoclonal antibody and use thereof
CN101528777B (zh) * 2006-10-26 2013-03-27 株式会社遗传科技 抗胞外基质蛋白的rgd氨基酸序列的抗体及其制法与用途
CN101293916A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
WO2009047283A2 (en) 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
KR20160074019A (ko) 2007-12-05 2016-06-27 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
PL2243829T3 (pl) 2008-01-11 2015-04-30 Astellas Pharma Inc Polepszone humanizowane przeciwciało anty-ludzka integryna alfa9,
AU2009203350B2 (en) 2008-01-11 2014-03-13 Gene Techno Science Co., Ltd. Humanized anti-alpha9 integrin antibodies and the uses thereof
CA2721716C (en) * 2008-04-24 2019-09-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
KR101599096B1 (ko) 2009-02-23 2016-03-02 가부시키가이샤 진 테크노 사이언스 항인간 α９ 인테그린 항체와 그 용도
CA2754591C (en) 2009-03-10 2018-03-06 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
EP2431738A4 (de) * 2009-05-12 2013-05-22 Innopharmascreen Inc Screening-verfahren für osteopontin-inhibitor und damit hergestellter inhibitor
EP2480665A4 (de) 2009-09-24 2013-04-03 Gene Techno Science Co Ltd Humanisierte antikörper gegen aminosäuresequenz rgd eines extrazellulären matrixproteins und ihre verwendung
US9737612B2 (en) 2011-03-01 2017-08-22 Novo Nordisk A/S Antagonistic DR3 ligands
GB2493540A (en) 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
KR102514173B1 (ko) 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
RU2749512C2 (ru) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
CN114867746A (zh) 2019-08-09 2022-08-05 小利兰·斯坦福大学董事会 抗骨桥蛋白的治疗性抗体
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US63241A (en) * 1867-03-26 Jacob green
US63247A (en) * 1867-03-26 hbtdeick
US705842A (en) * 1901-10-25 1902-07-29 Daniel M Moroney Machine for assembling links in making chain belts.
SU490302A1 (ru) * 1973-07-06 1979-08-05 Свердловский Научно-Исследовательский Институт Способ лечени больных ревматизмом
US5459060A (en) * 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1994020632A1 (fr) * 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih
EP0705842A2 (de) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Über Stimulation von Chondrozyten mit 1L-1Beta regulierte Genen
CZ296919B6 (cs) * 1994-10-07 2006-07-12 Chugai Seiyaku Kabushiki Kaisha Farmaceutický prípravek pro lécení chronické revmatické artritidy
US6414219B1 (en) * 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
MXPA01010332A (es) * 1999-04-15 2002-09-18 Childrens Medical Center Metodos y composiciones para modular una respuesta inmunitaria.
JP2002543775A (ja) * 1999-04-15 2002-12-24 チルドレンズ メディカル センター コーポレーション オステオポンチン由来の走化性および阻害性の薬剤およびその使用
US7504232B2 (en) * 2000-03-23 2009-03-17 Smithkline Beecham Corporation Method of screening for inhibitors of osteopontin
AU2002332290B2 (en) * 2001-09-25 2007-11-08 Astellas Pharma Inc. Recombinant anti-osteopontin antibody and use thereof

Also Published As

Publication number Publication date
JPWO2002081522A1 (ja) 2004-07-29
HUP0401561A2 (hu) 2004-11-29
RU2299888C2 (ru) 2007-05-27
EP1375518A4 (de) 2004-12-08
CZ20032697A3 (cs) 2004-01-14
PL366469A1 (en) 2005-02-07
US20080069815A1 (en) 2008-03-20
WO2002081522A1 (en) 2002-10-17
DE60229509D1 (de) 2008-12-04
CA2443330A1 (en) 2002-10-17
US20040234524A1 (en) 2004-11-25
CN100469793C (zh) 2009-03-18
CN1513000A (zh) 2004-07-14
ES2314040T3 (es) 2009-03-16
BR0208809A (pt) 2004-03-09
AU2002244968B2 (en) 2007-07-26
KR100881900B1 (ko) 2009-02-04
EP1375518A1 (de) 2004-01-02
EP1754719A2 (de) 2007-02-21
NO20034405L (no) 2003-12-05
NZ528483A (en) 2008-03-28
EP1754719A3 (de) 2007-05-16
RU2003132446A (ru) 2005-04-27
NO20034405D0 (no) 2003-10-02
AR033121A1 (es) 2003-12-03
EP1375518B1 (de) 2008-10-22
JP4230776B2 (ja) 2009-02-25
KR20030092022A (ko) 2003-12-03
MXPA03009052A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
ATE533508T1 (de) Cripto-blockierende antikörper und ihre verwendung
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
IL157142A0 (en) Modified antibodies and methods of use
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
DE602004017614D1 (de) Antikörper gegen den insulinähnlichen wachstumfaktor-i-rezeptor und verwendungen dafür
EP1551447A4 (de) Anti-addl-antikörper und ihre verwendungen
ATE471344T1 (de) Antikörper gegen vla-1
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE60106423D1 (de) Entzündungshemmende verbindungen und ihre verwendung
DE60229819D1 (de) Antriebsstrang und dessen Zusammenbaumethode
ATE420642T1 (de) Neue formulierungen und ihre verwendung
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE50214357D1 (de) Zahnradpaarung und deren Verwendung
DE50214244D1 (de) Klauenpolläufer und dessen herstellverfahren
DE60230162D1 (de) Polymerisate und ihre verwendung
DE60216376D1 (de) Verbundklebstoff und dessen Verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
IL172510A0 (en) Antibodies and uses thereof
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
IL166063A0 (en) Antibodies and uses thereof
DE60222252D1 (de) Acrylester und ihre verwendung
DE50300769D1 (de) Erdalkalialuminosilicatglas und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties